8EV Stock Overview
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Theracryf Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.0005 |
52 Week High | UK£0.032 |
52 Week Low | UK£0.0005 |
Beta | 1.44 |
1 Month Change | 0% |
3 Month Change | -87.50% |
1 Year Change | -98.25% |
3 Year Change | -99.38% |
5 Year Change | -99.77% |
Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
8EV | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 1.8% | -1.2% |
1Y | -98.2% | -19.8% | 1.8% |
Return vs Industry: 8EV underperformed the German Biotechs industry which returned -21.6% over the past year.
Return vs Market: 8EV underperformed the German Market which returned 2.2% over the past year.
Price Volatility
8EV volatility | |
---|---|
8EV Average Weekly Movement | 25.3% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8EV's share price has been volatile over the past 3 months.
Volatility Over Time: 8EV's weekly volatility has decreased from 54% to 25% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 10 | Huw Jones | theracryf.com |
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma and Phase I clinical trials for the treatment of neurodevelopmental disorders, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addictive behaviors; orexin 1 antagonist that is in late preclinical stage for the treatment of anxiety; and molecule DAT inhibitor, which is in late preclinical stage targeting fatigue and narcolepsy.
Theracryf Plc Fundamentals Summary
8EV fundamental statistics | |
---|---|
Market cap | €3.75m |
Earnings (TTM) | -€3.92m |
Revenue (TTM) | €979.73k |
3.8x
P/S Ratio-1.0x
P/E RatioIs 8EV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
8EV income statement (TTM) | |
---|---|
Revenue | UK£838.00k |
Cost of Revenue | UK£5.17m |
Gross Profit | -UK£4.33m |
Other Expenses | -UK£974.00k |
Earnings | -UK£3.35m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0078 |
Gross Margin | -516.35% |
Net Profit Margin | -400.12% |
Debt/Equity Ratio | 0% |
How did 8EV perform over the long term?
See historical performance and comparison